Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of NOS activity on lenvatinib in unresectable hepatocellular carcinoma
jRCT1030210283Recruiting
- Sponsor
- Kitasato University
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Kitasato University. Primary endpoint: Change in NOS activity. Started Aug 2021; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1030210283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030210283.